Heart Failure
Conditions
Keywords
Ventricular Assist Device
Brief summary
This study is meant to predict the outcome of VAD therapy, by forming a VAD registry for quality assessment, research, and real-time monitoring of patients on VAD therapy. The goal is to optimize the use of VAD therapy for patients, to create an online quality measurement tool for VAD treatment, and to create algorithms to estimate the prognosis for patients getting a VAD.
Detailed description
Patients eligible for VAD are being sampled before surgery for plasma as well as peripheral blood cells. After surgery patients are being sampled again at 24 h and 7 days. Inflammatory response is being monitored on gene expression as well as cell level and on cytokine level in relation to the outcome.
Interventions
None listed
Sponsors
Corewell Health West
Study design
Observational model
COHORT
Time perspective
OTHER
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subject is ≥ 18 years of age 2. Subject is treated with a VAD at the Butterworth Campus, Spectrum Health.
Exclusion criteria
1. Subject is less than 18 years of age. 2. Known prisoners of the state. 3. Subject is pregnant. 4. Non- English speaking patients will be excluded from the blood sub-study
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| One year mortality | One year | Mortality will be assessed yearly. |
Secondary
| Measure | Time frame |
|---|---|
| Cytokine Analysis | Pre-implant, within 24 hours of implant, and 7 days post-implant |
| Inflammatory cell subtype | Pre-implant, within 24 hours of implant, and 7 days post-implant |
| Hospital readmissions | Will be assessed yearly until death or explant |
Countries
United States
Outcome results
None listed